GlycoMimetics CSO John Magnani to depart March 31; consulting through June 2024

CRESCENT BIOPHARMA, INC.

Dr. John Magnani, SVP Research and CSO, employment ends March 31, 2023.
Severance of $40,000 payable in equal installments over 3 months after separation.
Company will pay COBRA premiums for 15 months post-separation.
Consulting agreement from April 1, 2023 through June 30, 2024 for continued equity vesting.
Consulting services provided at request of CEO or designee.

item 5.02

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Departed

John Magnani

Senior Vice President of Research and Chief Scientific Officer

CBIO · CRESCENT BIOPHARMA, INC.

Effective: 2023-03-31
Filed: February 21, 2023, 6:59 PM ET

On February 21, 2023, GlycoMimetics, Inc. (the “ Company ”) and Dr. John Magnani, the Company’s Senior Vice President of Research and Chief Scientific Officer, entered into an agreement (the “ Transition Agreement ”) pursuant to which the Company and Dr. Magnani have agreed that his employment with the Company will end on March 31, 2023

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

John Magnani departed as Senior Vice President of Research and Chief Scientific Officer at CRESCENT BIOPHARMA, INC..

Action: agreed that his employment will end
Role: Senior Vice President of Research and Chief Scientific Officer

Exact text from the filing

On February 21, 2023, GlycoMimetics, Inc. (the “ Company ”) and Dr. John Magnani, the Company’s Senior Vice President of Research and Chief Scientific Officer, entered into an agreement (the “ Transition Agreement ”) pursuant to which the Company and Dr. Magnani have agreed that his employment with the Company will end on March 31, 2023

View on SEC.gov

CRESCENT BIOPHARMA, INC. filing history →

Source: SEC EDGAR

accession 0001558370-23-001631

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.